Publications

The EAVI2020 project has contributed to many scientific publications. Below is a list of these publications and their journal links. All are freely accessible and acknowledge EAVI2020’s funding body, the European Commission:

• • • Gallinaro, A., Borghi, M., Pirillo, M.F., Cecchetti, S., Bona, R., Canitano, A., Michelini, Z., Di Virgilio, A., Olvera, A., Brander, C., Negri & D., Cara, A. (2020). Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice. Molecular Therapy Methods & Clinical Development. DOI: 10.1016/j.omtm.2020.01.013

• • • Oriol-Tordera, B., Berdasco, M., Llano, A., Mothe, B., Gálvez, C., Martinez-Picado, J., Carrillo, J., Blanco, J., Duran-Castells, C., Ganoza, C., Sanchez, J., Clotet, B., Calle, M.L., Sanchez-Pla, A., Esteller, M., Brander, C. & Ruiz-Riol, M. (2020). Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control. PLOS Pathogens. DOI: 10.1371/journal.ppat.1008678

• • • Yi-Yu, L., Belle, I., Blasi, M., Min-Nung, H., Buckley, A.F., Rountree, W., Klotman, M.E., Cara, A. & Negri, D. (2020). Skeletal muscle is an antigen reservoir in integrase-defective lentiviral vector-induced long-term immunity. Molecular Therapy Methods & Clinical Development. DOI: 10.1016/j.omtm.2020.03.008

• • • Blasi, M., Wescott, E.C., Baker, E.J., Mildenberg, B., LaBranche, C., Rountree, W., Haynes, B.F., Saunders, K.O., Moody, M.A., Negri, D., Santra, S., Cara, A. & Klotman, M.E. (2020). Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. NPJ Vaccines. DOI: 10.1038/s41541-020-0186-5

• • • Silva-Arrieta, S., Goulder, P.J.R. & Brander, C. (2020). In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction. PLOS Pathogens. DOI: 10.1371/journal.ppat.1008607

• • • Bailon, L.,  Mothe, B., Berman, C. & Brander, C. (2020). Novel Approaches Towards a Functional Cure of HIV/AIDS. DRUGS. DOI: 10.1007/s40265-020-01322-y

• • • Mohamed, Y.S., Borthwick, N.J., Moyo, N., Murakoshi, H., Akahoshi, T., Siliquini, F. , Hannoun, Crook, A., Hayes, P., Fast, P.E., Mutua, G., Jaoko, W., Silva-Arrieta, S., Llano, A., Brander, C., Takiguchi, M. & Hanke, T. (2020). Specificity of CD8 + T-Cell Responses Following Vaccination With Conserved Regions of HIV-1 in Nairobi, Kenya. Vaccines. DOI: 10.3390/vaccines8020260

• • • Mothe, B., Rosás-Umbert, M., Coll, P., Manzardo, C., Puertas, M.C., Morón-López, S., Llano, A., Miranda, C., Cedeño, S., López, M., Alarcón-Soto, Y., Melis, G.G., Langohr, K., Barriocanal, A.M., Toro, J., Ruiz, I., Rovira, C., Carrillo, A., Meulbroek, M., Crook, A., Wee, E.G., Miró, J.M., Clotet, B., Valle, M., Martinez-Picado, J., Hanke, T., Brander, C., Moltó, J. & The BCN02 Study Investigators (2020). HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). Immunol. DOI: 10.3389/fimmu.2020.00823

• • • Rosás-Umbert, M., Ruiz-Riol, M., Fernández, M.A., Marszalek, M., Coll, P., Manzardo, C., Cedeño, S., Miró, J.M., Clotet, B., Hanke, T., Moltó, J., Mothe, B., Brander, C. & The BCN02 Study Group (2020). In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial. Immunol. DOI: 10.3389/fimmu.2020.00418

• • • Borthwick, N., Silva-Arieta, S., Llano, A., Takiguchi, M., Brander, C. & Hanke, T. (2020). Novel nested peptide epitopes recognized by CD4+ T cells induced by HIV-1 conserved-region vaccines. Vaccines. DOI: 10.3390/vaccines8010028

• • • Suleiman, E., Mayer, J., Lehner, E., Kohlhauser, B., Katholnig, A., Batzoni, M., Damm, D., Temchura, V., Wagner, A., Überla, K. & Vorauer-Uhl, K. (2020). Conjugation of Native-Like HIV-1 Envelope Trimers onto Liposomes Using EDC/Sulfo-NHS Chemistry: Requirements and Limitations. Pharmaceutics. DOI: 10.3390/pharmaceutics12100979

• • • Blasi, M., Negri, D., Saunders, O.K., Baker, J.E., Stadtler, H., LaBranche, C., Mildenberg, B., Morton, G., Ciarla, A., Shen, X., Wang, Y., Rountree, W., Balakumaran, B., Santra, S., Haynes, F.B., Moody, M.A., Cara, A. & Klotman, E.M. (2020). Immunogenicity, safety and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. npj Vaccines. DOI:10.1101/2020.03.06.980680

• • • Caillat, C., Guilligay, D., Sulbaran, G. & Weissenhorn, W. (2020). Neutralizing Antibodies Targeting HIV-1 gp41. Vaccines. DOI: 10.3390/v12111210

• • • Schorcht, A., Van den Kerkhof, T., Cottrell, C., Allen, J., Torres, V., Behrens, A.J., Schermer, E., Burger, J., De Taeye, S., Torrents de la Pena, A., Bontjer, I., Gumbs, S., Ozorowski, G., LaBranche, C., De Val, N., Yasmeen, A., Klasse, P.J., Montefiori, D., Moore, J.P., Schuitemaker, H., Crispin, M., Van Gils, M.J., Ward, A.B. & Sanders, R.W. (2020). Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. Journal of Virology. DOI: 10.1128/JVI.01214-20

• • • Yuan, M., Cottrell, C.A., Ozorowski, G., Van Gils, M.J., Kumar, S., Wu, N.C., Sarkar, A., Torres, J.L., De Val, N., Copps, J., Moore, J.P., Sanders, R.W., Ward, A.B. & Wilson, I.A. (2020). Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies. Cell Host & Microbe. Vol 25(6). DOI: 10.1016/j.chom.2019.04.011.

• • • Wee, E.G.,  Moyo, N.A., Saunders. K. O., LaBranche. C., Donati, F., Capucci. S., Parks, R., Borthwick, N., Hannoun, Z., Montefiori, D.C., Haynes, B.F., Hanke, T. (2019). Parallel induction of CH505 B-cell ontogeny-guided neutralizing antibodies and tHIVconsvX conserved mosaic-specific T cells against HIV. Molecular Therapy – Methods & Clinical Development. Vol 14, pp 148-160. DOI: 10.1016/j.omtm.2019.06.003

• • • Vieillard, V., Combadière, B., Tubiana, R., Launay, O., Pialoux, G., Cotte, L.,  Girard, PM., Simon, A., Dudoit, Y., Reynes, J., Rockstroh, J., Garcia, F., Gatell, J., Devidas, A., Yazdanpanah, Y., Weiss, L., Fätkenheuer, G., Autran, B., Joyeux, D., Gharakhanian, S., Debré, P., Katlama, C. (2019). HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomized phase 2 trial. npj Vaccines Volume 4(25). DOI: 10.1038/s41541-019-0117-5

• • • Suleiman, E., Damm, D., Batzoni, M., Temchura, V., Wagner, A., Überla, K., & Vorauer-Uhl, K. (2019). Electrostatically Driven Encapsulation of Hydrophilic, Non-Conformational Peptide Epitopes into Liposomes. Pharmaceutics. DOI: 10.3390/pharmaceutics11110619

• • • Pinto,D., Fenwick, C., Caillat, C., Silacci, C., Guseva, S., Dehez, F., Chipot, C., Barbieri, S., Minola, A., Jarrossay, D., Tomaras,  G.D., Shen, X., Riva, A., Tarkowski, M., Schwartz, O., Bruel, T., Dufloo, J., Seaman, M.S., Montefiori, D.C., Lanzavecchia, A., Corti, D., Pantaleo, G. & Weissenhorn, W. (2019). Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. Cell Host & Microbe. DOI: 10.1016/j.chom.2019.09.016

• • • Rosás-Umbert, M., Llano, A., Bellido, R., Olvera, A., Ruiz-Riol, M., Rocafort, M., Fernández, M.A., Cobarsi, P., Crespo, M., Dorrell, L., del Romero, J., Alcami, J., Paredes, R., Brander, C., Mothe, B.  (2019). Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers. Journal of Virology, volume 93 (4) e01436-18; DOI: 10.1128/JVI.01436-18

• • • Yuan, M., Cottrell, C.A., Ozorowski, G., van Gils, M.J., Kumar, S., Wu, N.C., Sarkar, A., Torres, J.L. Val, N., Copps, J., Moore, J.P., Sanders, R.W., Ward, A.B., Wilson, I.A. (2019). Conformational plasticity in the HIV-1 fusion peptide facilitates recognition by broadly neutralizing antibodies. Cell Host & Microbe. Volume 25(6), June 12, Pages 873-883.e5. DOI: 10.1016/j.chom.2019.04.011

• • • Brouwer, P.J.M., Antanasijevic, A., Berndsen, Z., Yasmeen, A., Fiala, B., Bijl, T.P.L., Bontjer, I., Bale, J.B., Sheffler, W., Allen, J.D., Schorcht, A., Burger, J.A., Camacho, M., Ellis, D., Cottrell, C.A., Behrens, AJ., Catalano, M., del Moral-Sánchez, I., Ketas, T.J., LaBranche, C., van Gils, M.J., Sliepen, K., Stewart, L.J., Crispin, M., Montefiori, D.C., Baker, D., Moore, J.P., Klasse, P.J., Ward, A.B., King, N.P., Sanders, R.W. (2019). Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. Nature Communications. Volume 10 (4272). September 19. DOI: 10.1038/s41467-019-12080-1

• • • Torrents de la Peña, A., Rantalainen, K., Cottrell, C.A., Allen, J.D., van Gils, M.J., Torres, J.L., Crispin, M., Sanders, R.W., Ward, A.B. (2019). Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics. PLoS Pathogens. Volume 15(7). DOI: 10.1371/journal.ppat.1007920

• • • Watanabe, Y., Bowden, T.A., Wilson, I.A., Crispin, M. (2019). Exploitation of glycosylation in enveloped virus pathobiology. Biochim Biophys Acta Gen Subj. Oct. Volume 1863(10). Pp 1480-1497. DOI: 10.1016/j.bbagen.2019.05.012.

• • • Broset E, Saubi N, Guitart N, Aguilo N, Uranga S, Kilpeläinen A, Eto Y, Hanke T, Gonzalo-Asensio J, Martín C, and Joseph-Munné J. (2019). MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice. Molecular Therapy Methods & Clinical Development. DOI: 10.1016/j.omtm.2019.01.014

• • • Seabright G.E., Doores K.J., Burton D.R., and Crispin M. (2019). Protein and Glycan Mimicry in HIV Vaccine Design. Journal of Molecular Biology. DOI: 10.1016/j.jmb.2019.04.016

• • • Vázquez Bernat N, Corcoran M, Hardt U, Kaduk M, Phad G.E., Martin M, and Karlsson H.G.B. (2019). High-Quality Library Preparation for NGS-Based Immunoglobulin Germline Gene Inference and Repertoire Expression Analysis. Frontiers in Immunology. Vol 10. DOI: 10.3389/fimmu.2019.00660

• • • Heß R, Storcksdieck Genannt Bonsmann M, Lapuente D, Maaske A, Kirschning C, Ruland J, Lepenies B, Hannaman D, Tenbusch M, and Überla K. (2019). Glycosylation of HIV Env Impacts IgG Subtype Responses to Vaccination. Viruses. 11(2). DOI: 10.3390/v11020153

• • • Sliepen K, Han B.W., Bontjer I, Mooij P, Garces F, Behrens A, Rantalainen K, Kumar S, Sarkar A, Brouwer P.J.M., Hua Y, Tolazzi M, Schermer E, Torres J.L., Ozorowski G, van der Woude P, de la Peña A.T., van Breemen M.J., Camacho-Sánchez J.M., Burger J.A., Medina-Ramírez. M, González. N, Alcami.J, LaBranche.C, Scarlatti G, van Gils M.J., Crispin M, Montefiori D.C., Ward A.B., Koopman G, Moore J.P., Shattock R.J., Bogers W.M., Wilson I.A., and Sanders. R.W. (2019). Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature Communications DOI: 10.1038/s41467-019-10262-5

• • • Kilpeläinen A, Saubi N, Guitart N, Moyo N, Wee E.G., Ravi K, Hanke T, and Joseph J. (2019). Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice. Frontiers in Immunology. Vol 10. DOI: 10.3389/fimmu.2019.00923

• • • Ruiz-Riol M & Brander C. (2019). Can we just kick-and-kill HIV: possible challenges posed by the epigenetically controlled interplay between HIV and host immunity. Immunotherapy, 11(11). Future Medicine, UK. DOI: 10.2217/imt-2019-0092

• • • Brinkkemper M & Sliepen K. Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies. (2019). Vaccines, 7(3). MDPI, Switzerland. DOI: 10.3390/vaccines7030076

• • • Kilpeläinen, A Saubi, N Guitart, N Olvera, A Hanke, T Brander, C Joseph, J. (2019). Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice. Vaccines 7(78). MDPI, Switzerland. DOI: 10.3390/vaccines7030078

• • • Combadière B, Beaujean M, Chaudesaigues C, Vieillard V. (2019). Peptide-Based Vaccination for Antibody Responses Against HIV. Vaccines, 7(3). MDPI, Switzerland. DOI: 10.3390/vaccines7030105

• • • Eggink D, Bontjer I, de Taeye S.W, Langedijk J.P.M, Berkhout B, Sanders R.W. (2019). HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry. Journal of Biological Chemistry. DOI: 10.1074/jbc.RA119.007360

• • • Beltran-Pavez, C., Ferreira, C.B., Merino-Mansilla, A., Fabra-Garcia, A., Casadella, M., Noguera-Julian, M., Paredes, R., Olvera, A., Haro, I., Brander, C., Garcia, F., Gatell, J.M., Yuste, E., Sanchez-Merino, V. (2018)  Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. PLoS ONE, 13(12): e0208345. December 19. DOI: 10.1371/journal.pone.0208345

• • • Viegas E.O., Kroidl A, Munseri P.J., Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stöhr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb M.L., Weber J, McCormack S, Biberfeld G, Jani I.V., Sandström E, Lyamuya E, and TaMoVac study group. (2018). Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. PLOS ONE, 13(11).  DOI: 10.1371/journal.pone.0206838

• • • Crispin M, Ward A.B., and Wilson I.A. (2018). Structure and Immune Recognition of the HIV Glycan Shield. Annual Review of Biophysics, 47(1). DOI: 10.1146/annurev-biophys-060414-034156

• • • Lopez E, Shattock R.J., Kent S.J., and Chung A.W. (2018). The Multifaceted Nature of Immunoglobulin A and Its Complex Role in HIV. AIDS Research and Human Retroviruses, 34(9). DOI: 10.1089/aid.2018.0099

• • • Moyo N, Vogel A.B., Buus S, Erbar S, Wee E.G., Sahin U, and Hanke T. (2018). Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA. Molecular Therapy Methods & Clinical Development DOI: 10.1016/j.omtm.2018.10.010

• • • Lucar O, Su B, Potard V, Samri A, Autran B, Moog C, Debré P, and Vieillard V. (2017). Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status. EBioMedicine, 22. DOI: 10.1016/j.ebiom.2017.07.007

• • • Borthwick N, Lin Z, Akahoshi T, Llano A, Silva-Arrieta S, Ahmed T, Dorrell L, Brander C, Murakoshi H, Takiguchi M, and Hanke T. (2017). Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines. PLoS ONE, 12(4). DOI: 10.1371/journal.pone.0176418

• • • Ruiz-Riol D, Berdnik A, Llano B, Mothe C, Gálvez S, Pérez-Álvarez B, Oriol-Tordera A, Olvera S, Silva-Arrieta M, Meulbroek F, Pujol J, Coll J, Martinez-Picado C, Ganoza J, Sanchez G, Gómez T, Wyss-Coray C, and Brander C (2017). Identification of Interleukin-27 (IL-27)/IL-27 Receptor Subunit Alpha as a Critical Immune Axis for In Vivo HIV Control. Journey of Virology, 91(16). DOI: 10.1128/JVI.00441-17

• • • Wee E.G, Ondondo B, Berglund P, Archer J, McMichael A.J, Baltimore D, Meulen J.H, and Hanke T. (2017).HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells.  Molecular Therapy, 25(2). DOI: 10.1016/j.ymthe.2016.12.004

• • • Capucci S, Wee EG, Schiffner T, LaBranche CC, Borthwick N, Cupo A, Dodd J, Dean H, Sattentau Q, Montefiori D, Klasse P.J, Sanders R.W, Moore J.P, and Hanke T. (2017). HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. PLoS ONE, 12(8). DOI: 10.1371/journal.pone.0181886

• • • Soldemo M and Hedestam G.B.K. (2017). Env-Specific Antibodies in Chronic Infection versus in Vaccination. Frontiers in Immunology, 8(1057). DOI: 10.3389/fimmu.2017.01057

• • • Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye S.W., Moral-Sanchez I.D., McGuire A.T, Yasmeen A, Behrens A, Ozorowski G, van den Kerkhof T.L.G.M., Freund N.T, Dosenovic P, Hua Y, Gitlin A.D., Cupo A, van der Woude P, Golabek M, Sliepen K, Blane T, Kootstra N, van Breemen M.J., Pritchard L.K., Stanfield r.L., Crispin. M, Ward A.B., Stamatatos L, Klasse P.J., Moore J.P, Nemazee D, Nussenzweig M.C, Wilson I.A, and Sanders R.W. (2017). Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. Journal of Experimental Medicine, 214(9) DOI: 10.1084/jem.20161160

• • • Medina-Ramírez M, Sanders R.W, and Sattentau Q.J. (2017).Stabilized HIV-1 envelope glycoprotein trimmers for vaccine use.  Current Opinion HIV AIDS, 12(3). DOI: 10.1097/COH.0000000000000363

• • • Mahant A, Saubi N, Eto Y, Guitart N, Gatell J.M., Hanke T, and Joseph. J (2017). Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity. Human Vaccines and Immunotherapeutics, 13( 8). DOI: 10.1080/21645515.2017.1316911

• • • Sanders R.W., and Moore J.P. (2017).Native-like Env trimers as a platform for HIV-1 vaccine design.  Immunological Reviews, 275. DOI: 10.1111/imr.12481

• • • Behrens A, and Crispin M. (2017). Structural principles controlling HIV envelope glycosylation. Current Opinion in Structural Biology. DOI: 10.1016/j.sbi.2017.03.008

• • • Temchura V, and Überla K. (2017). Intrastructural help: improving the HIV-1 envelope antibody response induced by virus-like particle vaccines. Current Opinion in HIV and AIDS, 12(3). DOI: 10.1097/COH.0000000000000358

• • • Hinkula J, Petkov S, Ljungberg K, Hallengärd D, Bråve A, Isaguliants M, Falkeborn T, Sharma S, Liakina V, Robb M, Eller M, Moss B, Biberfeld G, Sandström E, Nilsson C, Markland K, Blomberg P, and Wahren B. (2017). HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV. Heliyon, 3(6).  DOI: 10.1016/j.heliyon.2017.e00339

• • • Kratochvil S, McKay P.F., Kopycinski J.T., Bishop C, Hayes P.J., Muir L, Pinder C.L., Cizmeci D, King D, Aldon Y, Wines B.D., Hogarth M, Chung A.W., Kent S.J., Held K, Geldmacher C, Dally L, Santos N.S., Cole T, Gilmour J, Fidler S, and Shattock R.J. (2017). A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. Frontiers in Immunology, 8. DOI: 10.3389/fimmu.2017.00595.

• • • Stenler K. E., Lundin L, Hansen S, Petkov N, Mozafari M, Isaguliants P, Blomberg C.I.E, Smith D.M, Goldenberg C.H., Chang K. Ljungberg J. Hinkula, and Wahren B. (2017) Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses. Human Vaccines & Immunotherapeutics, 13(12). DOI: 10.1080/21645515.2017.1338546

• • • Behrens A, Weston B.S., and Crispin. M (2017). Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1. Expert Review of Proteomics, 14(10). DOI: 10.1080/14789450.2017.1376658

• • • Olvera A, Martinez J.P., Casadellà M, Llano A, Rosás M, Mothe B, Ruiz-Riol M, Arsequell G, Valencia Gr, Noguera-Julian M, Paredes R, Meyerhans A, and Brander C. (2018). Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy In Vitro. Frontiers in Immunology, DOI: 10.3389/fimmu.2017.02010

• • • Schiffner T, Pallesen J, Russell R.A., Dodd J, de Val N, LaBranche C, Montefiori D, Tomaras G.D., Shen X, Harris S.L., Moghaddam A.E., Moghaddam A.E., Kalyuzhniy O, Sanders R.W., McCoy L.E., Moore J.P., Ward A.B., and Sattentau Q.J. (2018). Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. PLOS Pathogens, 14(5). DOI: 10.1371/journal.ppat.1006986

• • • Elsayed H, Nabi G, McKinstry W.J., Khoo K.K., Mak J, Salazar A.M., Tenbusch M, Temchura V, and U¨ berla K. (2018). Intrastructural help: harnessing T helper cells induced by licensed vaccines for improvement of HIV Env antibody responses to virus-like particle vaccines. Journal of Virology, DOI: 10.1128/JVI.00141-18

• • • González N, McKee K, Lynch RM, Georgiev IS, Jimenez L, Grau E, Kwong P.D., Mascola J.R., and Alcamí, J. (2018). Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term nonprogressors. PLoS ONE, 13(3). DOI: 10.1371/journal.pone.0193773

• • • Aldon Y, McKay P.F., Allen J, Ozorowski G, Felfödiné Lévai R, Tolazzi M, Rogers P, He L, de Val N, Fábián K, Scarlatti G, Zhu J, Ward A.B., Crispin M, and Shattock R.J. (2018). Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers. CelRep, 24(12). DOI: 10.1016/j.celrep.2018.08.051

• • • Cheeseman H.M., Day S, McFarlane L.R., Fleck S, Miller A, Cole T, Sousa-Santos N, Cope A, Cizmeci D, Tolazzi M, Hwekwete E, Hannaman D, Kratochvil S, McKay P.F., Chung A.W., Kent S.J., Cook A, Scarlatti G, Abraham S, Combadiere B, McCormack S, Lewis D.J., and Shattock R.J. (2018). Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine. Human Gene Therapy, 29(9). DOI: 10.1089/hum.2018.075

• • • Anderson J, Olafsdottir T.A., Kratochvil S, McKay P.F., Östensson M, Persson J, Shattock R.J., and Harandi A.M. (2018). Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans. Frontiers in Immunology, 9. DOI: 10.3389/fimmu.2018.00301

• • • Kratochvil S, McKay P.F., Chung A.W., Kent S.J., Gilmour J, and Shattock R.J. (2017). Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination. Frontiers in Immunology, 8. DOI: 10.3389/fimmu.2017.01883

• • • Pinder C.L., Kratochvil S, Cizmeci D, Muir L, Guo Y, Shattock R.J., and McKay P.F., (2017). Isolation and Characterization of Antigen-Specific Plasmablasts Using a Novel Flow Cytometry–Based Ig Capture Assay. Journal of Immunology, 199(12) DOI: 10.4049/jimmunol.1701253

• • • Coss K.P., Vasiljevic S, Pritchard L.K., Krumm S.A., Glaze M, Madzorera S, Moore P.L., Crispin M, and Doores K.J. (2016). HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual. Journal of Virology, 90(24). DOI: 10.1128/JVI.01542-16

• • • Sanchez-Merino A, Fabra-Garcia N, Gonzalez D, Nicolas A, Merino-Mansilla C, Manzardo J, Ambrosioni A, Schultz A, Meyerhans J. R., Mascola J. M., Gatell J, Alcami J. M., Miro E., and Yuste. (2016). Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. Journal of Virology, 90(11). DOI: 10.1128/JVI.00049-16

• • • van Gils M.J., van den Kerkhof T.L., Ozorowski G, Cottrell C.A., Sok D, Pauthner M, Pallesen J, de Val N, Yasmeen A, de Taeye S.W., Schorcht A, Gumbs S, Johanna I, Saye-Francisco K, Liang C.H., Landais E, Nie X, Pritchard L.K., Crispin M, Kelsoe G, Wilson I.A., Schuitemaker H, Klasse P.J., Moore J.P., Burton D.R., Ward A.B., Sanders R.W. (2016). An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nature Microbiology, 2(16199). DOI: 10.1038/nmicrobiol.2016.199